<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04685876</url>
  </required_header>
  <id_info>
    <org_study_id>20-790</org_study_id>
    <nct_id>NCT04685876</nct_id>
  </id_info>
  <brief_title>Comparing TAP Blocks Bupivacaine, and Placebo for Plane</brief_title>
  <acronym>CLEVELAND</acronym>
  <official_title>Comparison of Liposomal Bupivacaine, Plain Bupivacaine, and Placebo for Transversus Abdominis Plane Blocks: A Randomized, Blinded Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will prospectively compare the analgesic efficacy of TAP blocks with liposomal&#xD;
      bupivacaine, plain bupivacaine, and placebo in patients who are scheduled for major abdominal&#xD;
      surgery. The primary aim is to assess the duration of the local analgesia (determined by&#xD;
      pinprick and cold) in all four quadrants. Comparing opioid consumption and pain scores is a&#xD;
      secondary aim. All aims will be assessed over 72 hours or the duration of hospitalization if&#xD;
      shorter.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose a randomized double-blind trial comparing TAP blocks with liposomal&#xD;
      bupivacaine, plain bupivacaine, and placebo in patients having elective abdominal surgery.&#xD;
&#xD;
      After eligibility is confirmed, patients will receive complete information about the study&#xD;
      both verbally and in writing. Informed consent will be obtained from the patients prior to&#xD;
      randomization and study-specific procedures.&#xD;
&#xD;
      Randomization will be based on computer-generated codes and use random-sized blocks.&#xD;
      Allocations will be concealed until the morning of surgery where they will be provided by a&#xD;
      web-based system. Randomization will be stratified by study site and chronic opioid use,&#xD;
      defined by opioid use for more than 30 consecutive days within three preoperative months, at&#xD;
      a daily dose of 15 mg or more of morphine or equivalent. Randomization will also be&#xD;
      stratified according to anticipated type of surgery (open vs. laparoscopic-assisted).&#xD;
      Clinicians doing the blocks will not be involved in data collection and all the evaluators&#xD;
      will be blinded to group allocations.&#xD;
&#xD;
      All blocks will be performed preoperatively or after induction of anesthesia by attending&#xD;
      anesthesiologists or regional anesthesia fellows who are experienced in TAP blocks.&#xD;
      Premedication will be administered at the discretion of the attending anesthesiologist and&#xD;
      standard monitors will be used. Patients will be given 1 g oral acetaminophen an hour before&#xD;
      surgery, and an additional 500 mg every 6 hours for 72 hours after surgery starting with oral&#xD;
      intake.&#xD;
&#xD;
      Patients will be randomly assigned to: 1) 4-quadrant TAP block with liposomal bupivacaine; 2)&#xD;
      4-quadrant TAP block with plain bupivacaine; or, 3) placebo (normal saline). An in-plane&#xD;
      ultrasound will be guide TAP blocks. Two subcostal injections will be applied by placing the&#xD;
      probe midline and then moving lateral along the subcostal margin identifying area between the&#xD;
      rectus abdominis sheath and the transversus abdominis muscle. The lateral two TAP block&#xD;
      injections will be applied in the midaxillary line between the thoracic cage and iliac crest&#xD;
      between external oblique and transversus abdominis muscles. Once the target area is&#xD;
      positioned, the following injections will be given, based on randomization:&#xD;
&#xD;
      Liposomal bupivacaine. 40 ml of plain bupivacaine 0.25% will be mixed with 20 ml liposomal&#xD;
      bupivacaine and 20 ml of saline. 20 ml of the mix will be injected at each location of the&#xD;
      4-quadrant TAP block.&#xD;
&#xD;
      Plain bupivacaine group. 50 ml of plain bupivacaine 0.5% will be combined with 30 ml of&#xD;
      normal saline making a total of 80 ml. 20 ml will be injected at each location of the&#xD;
      4-quadrant TAP block.&#xD;
&#xD;
      Placebo group; patients will receive total of 80 ml of normal saline, injected 20 ml in each&#xD;
      of the four-quadrant sites.&#xD;
&#xD;
      General anesthesia will be induced using propofol or etomidate, fentanyl, and rocuronium to&#xD;
      facilitate intubation. Anesthesia will be maintained with sevoflurane or isoflurane, along&#xD;
      with opioids and muscle relaxants as clinically indicated. However, intraoperative analgesic&#xD;
      use will be limited to fentanyl, a short-acting opioid.&#xD;
&#xD;
      Postoperatively, patients will be given intravenous patient-controlled analgesia and nurses&#xD;
      will be free to give additional opioid as clinically indicated. Hydromorphone will be the&#xD;
      default drug, but fentanyl will be substituted if necessary. Clinicians blinded to trial drug&#xD;
      will adjust analgesic management as necessary in an effort to keep verbal response pain&#xD;
      scores (details below) &lt;4 points on a 0-10 scale, with 10 being worst pain. When patients no&#xD;
      longer need PCA, they will be switched to as-needed hydromorphone or fentanyl.&#xD;
&#xD;
      A single dose of dexamethasone (4-8 mg) will be permitted for PONV prophylaxis, and inhaled&#xD;
      steroids will be permitted as necessary to treat reactive airway disease. The use of&#xD;
      non-steroidal anti-inflammatory drugs and gabapentinoids will be allowed as part of the ERAS&#xD;
      approach (enhanced recovery after surgery) according to hospital's clinical practice. Other&#xD;
      opioid-sparing medications such as ketamine and lidocaine patches will not be permitted&#xD;
      through the initial 72 postoperative hours.&#xD;
&#xD;
      Patients will be allowed to receive prophylactic anti-emetic (first choice ondansetron)&#xD;
      intraoperatively based on the risk assessment for nausea and vomiting. Postoperative&#xD;
      anti-emetics for symptomatic treatment will also be allowed; again ondansetron will be the&#xD;
      first choice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to return of sensation</measure>
    <time_frame>72 hours</time_frame>
    <description>The investigator evaluate when patients feels both ice and pinprick in at least 6 of the 8 designated test locations, or 75% of the covered points if the TAP block did not initially cover all eight locations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opioid Consumption</measure>
    <time_frame>72 hours</time_frame>
    <description>The investigators will compare the 3 randomized groups on opioid consumption over the first 72 hours</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">237</enrollment>
  <condition>Abdominal Surgery</condition>
  <arm_group>
    <arm_group_label>liposomal bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 ml of plain bupivacaine 0.25% will be mixed with 20 ml liposomal bupivacaine and 20 ml of saline. 20 ml of the mix will be injected at each location of the 4-quadrant TAP block.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>plain bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 ml of plain bupivacaine 0.5% will be combined with 30 ml of normal saline making a total of 80 ml. 20 ml will be injected at each location of the 4-quadrant TAP block.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients will receive total of 80 ml of normal saline, injected 20 ml in each of the four-quadrant sites.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal bupivacaine</intervention_name>
    <description>4-quadrant TAP block with liposomal bupivacaine</description>
    <arm_group_label>liposomal bupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plain bupivacaine</intervention_name>
    <description>4-quadrant TAP block with plain bupivacaine</description>
    <arm_group_label>plain bupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>placebo (normal saline).</description>
    <arm_group_label>Normal Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent;&#xD;
&#xD;
          -  18-85 years old;&#xD;
&#xD;
          -  ASA Physical Status 1-3;&#xD;
&#xD;
          -  Scheduled for elective open or laparoscopic-assisted abdominal surgery;&#xD;
&#xD;
          -  Anticipated hospitalization of at least three nights;&#xD;
&#xD;
          -  Expected requirement for parenteral opioids for at least 72 hours for postoperative&#xD;
             pain;&#xD;
&#xD;
          -  Able to use IV PCA systems.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hepatic disease, e.g. twice the normal levels of liver enzymes;&#xD;
&#xD;
          -  Kidney disease, e.g. twice the normal level of serum creatinine;&#xD;
&#xD;
          -  Bupivacaine sensitivity or known allergy;&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding;&#xD;
&#xD;
          -  Anticoagulants considered to be a contraindication for TAP blocks;&#xD;
&#xD;
          -  Surgeries with high port sites;&#xD;
&#xD;
          -  Weight &lt;50 kg.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Roberta Johnson</last_name>
    <phone>216-444-9950</phone>
    <email>johnsor13@ccf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hani Essber, MD</last_name>
    <phone>216-444-9950</phone>
    <email>essberh@ccf.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberta Johnson</last_name>
      <phone>216-444-9950</phone>
      <email>johnsor13@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Hani Essber, MD</last_name>
      <phone>216-444-9950</phone>
      <email>essberh@ccf.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 22, 2020</study_first_submitted>
  <study_first_submitted_qc>December 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2020</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

